Leaving the study early · patients with schizophrenia
Paliperidone palmitate leads to lower leaving the study early ‐ any reason Reported by trial author compared with placebo (high certainty).
1 finding from 1 review
Death by end of trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in death Reported by trial author compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in no clinically important change Number of people whose PANSS score… compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate showed no clear difference in relapse: recurrence of psychotic symptoms Reported by trial authors… compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Cost ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate probably leads to lower no clinically important change Number of people whose PANSS score… compared with placebo (moderate certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate probably leads to lower relapse: recurrence of psychotic symptoms Reported by trial author… compared with placebo (moderate certainty).
1 finding from 1 review
Average change in prolactin in men Serum prolactin level (ng/mL) · patients with schizophrenia
1 finding from 1 review
Average change in prolactin in women Serum prolactin level (ng/mL) · patients with schizophrenia
1 finding from 1 review
Change in weight (kg) · patients with schizophrenia
1 finding from 1 review
Health‐related quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
Paliperidone palmitate showed no clear difference in leaving the study early ‐ any reason Reported by trial author compared with risperidone long‐acting injection (high certainty).
1 finding from 1 review
Leaving the study early ‐ lack of efficacy Reported by trial author · patients with schizophrenia
Paliperidone palmitate probably leads to higher leaving the study early ‐ lack of efficacy Reported by trial author compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term · patients with schizophrenia
RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
1 finding from 1 review
Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review